Cytokinetics reported strong MyCorso commercialization, FDA approval to include Maple HCM data in an expanded label, and an Acacia SNDA submission planned this quarter. Germany reached over 50% new-to-brand share, and cash totaled $1.6 billion at quarter-end.
CYTK · Cytokinetics Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Cytokinetics reported revenue up 76% versus Q2, CMI market growth of 45% year-over-year, and new-to-brand share close to 45% after eight months on market; cash and investments totaled $1.6 billion.
Cytokinetics reported Mycorso Q3 net revenue of $44.5 million, up 76% from Q2, and remains on track to submit an FDA supplemental NDA for NHCM this quarter, with an FDA decision on MAPLE HCM data scheduled for November 14th.
Cytokinetics reported 74,630 thousand dollars in net product revenue for the nine months ended September 30, 2026; positive ACACIA-HCM results support a planned fourth quarter 2026 nHCM filing.
Cytokinetics reported third-quarter 2026 revenue of $47.6 million, including $44.5 million in MYQORZO net product revenue, and expects to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.